You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Topical application of heterologous protein-expressing Staphylococcus epidermidis for potential therapeutic treatment of skin diseasesSBC: Azitra Inc. Topic: NIAID
PROJECT SUMMARY Current treatment options for a number of skin diseases generally aim for symptomatic relief and fail to address underlying pathophysiological changes leading to skin disease In the case of genetic mutations that cause loss of function mutations supplementation of the missing protein is a viable approach to treatment However delivery of functional protein to the target keratino ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: PROFUSA, INC. Topic: NHLBI
DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
Simple, low cost assay for detection of HIV-1 antiretroviral resistance in resource-limited settingsSBC: Discidium Biosciences, LLC Topic: NIAID
Antiretroviral therapy has become a reality in resource limited settings thanks to entities such as PEFAR and the Global Fund However contrary to the therapeutic choice flexibility in developed countries all patients go on reverse transcriptase inhibitor RTI based first line regimens with more expensive protease and integrase inhibitor based regimens being reserved as second line therapy for ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Novici Biotech LLC Topic: NHLBI
DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: SUN BIOPHARMA, INC. Topic: 300
Project Summary Pancreatitis is a significant public health problem accounting for over $ Billion of health care costs annually Approximately one third of patients with acute pancreatitis will go on to have recurrent pancreatitis Of those about will progress to chronic pancreatitis a painful disease with an increased risk of both diabetes and pancreatic cancer More than of people w ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: BioIncept, LLC Topic: NICHD
ABSTRACT Perinatal hypoxic ischemic encephalopathy HIE affects to infants per every born Mortality from HIE can be up to and approximately of survivors suffer significant long term disability including cerebral palsy epilepsy and developmental disorders Damage during the acute phase of HIE is caused by a deficit in oxygen and glucose in the brain However increasing evide ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.SBC: Acumen Pharmaceuticals, Inc Topic: NIA
In the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are proposed National Institute on Aging and the Alzheimer s Association preclinical AD mild cognitive impairment MCI due to AD and dementia due to AD The preclinical stage is proposed to begin ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: COGMETRIC LLC Topic: NIA
ABSTRACT Detecting change in neuropsychological functioning over time is critical for proper diagnosis and management of many neurological psychiatric and psychological conditions It is well documented that most commonly used cognitive assessments produce significant retest effects such as practice and regression to the mean effects Retest effects can cause substantial changes in test score ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: ARISAN THERAPEUTICS INC Topic: NIAID
Project Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastructure and workflow in clinical settings of both developing and developed regions In addition being able to distinguish among multiple potential infectious pathogens in a single test is of great impor ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: STONESTABLE, INC. Topic: NIAID
The goal of this Phase I STTR grant proposal is to stabilize live attenuated influenza vaccine LAIV using a temporary silica coating that is removed in vivo In so doing we will establish a broader technology to eliminate the cold chain required for transport of heat and cold labile vaccines Many vaccines are unstable under ambient environmental conditions Currently vaccines are either stabil ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health